CAMBRIDGE, Mass. , Sept. 6, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead
- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources - - Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study of MM-121 in metastatic non-small cell lung cancer and Phase 1 study of MM-310 in solid tumors
CAMBRIDGE, Mass. , July 31, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, August 7, 2018. The call will provide an update on Merrimack's recent
- Non-dilutive financing strengthens cash position - - Multiple clinical read-outs expected later this year - CAMBRIDGE, Mass. , July 2, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the
- CARRIE study did not meet primary or secondary endpoints - - Company ceases development of MM-141 - - Focus remains on advancing Merrimack's promising clinical and preclinical pipeline, with two additional clinical study readouts anticipated in 2H 2018 - CAMBRIDGE, Mass.
CAMBRIDGE, Mass. , May 29, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present two posters at the American Society of Clinical Oncology ( ASCO ) Annual Meeting, June 1-5,
- Three clinical readouts expected in 2018, including data from two randomized Phase 2 studies - - Conference call at 8:30 am ET today - CAMBRIDGE, Mass. , May 8, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined
CAMBRIDGE, Mass. , May 1, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its first quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, May 8, 2018. The company will provide an update on Merrimack's recent
CAMBRIDGE, Mass. , April 9, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present preclinical data at the 2018 American Association for Cancer Research (AACR) Annual Meeting,
- Strengthened the randomized Phase 2 SHERLOC study evaluating MM-121 in non-small cell lung cancer by expanding enrollment from 80 to 100 patients - - Dosed the first patient in randomized Phase 2 SHERBOC study evaluating MM-121 in metastatic breast cancer - - Announced the formation of a new
